PatientCrossroads CMD


           

Congenital Myasthenic Syndrome: Expanded Access Study of Amifampridine Phosphate

Primary Objective:
To provide patients with LEMS/CMS/downbeat nystagmus access to amifampridine phosphate therapy where physicians would like to treat with amifampridine phosphate
Secondary Objective:
To assess the long-term safety of amifampridine phosphate in patients with LEMS/CMS/downbeat nystagmus
Sponsor:
Catalyst Pharmaceutical Partners, Inc
 
Collaborator:
Voisin Consulting Life Sciences, Inc.
 
For more information about this study, please visit:
https://clinicaltrials.gov/ct2/show/NCT02189720?term=Nct02189720&rank=1